# RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

> **NCT00101972** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 53 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** monoclonal antibody RAV12

## Key facts

- **NCT ID:** NCT00101972
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101972, "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00101972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*